Charles River Laboratories has acquired early-stage contract research organization (CRO) Retrogenix, a provider of specialized bioanalytical services utilizing its proprietary cell microarray technology, for $48 million.   Based in the UK, Retrogenix offers cell microarray services for target receptor identification, off-target profiling, and target deconvolution on a wide range of novel therapeutics including biologics, cell therapies, and small molecules. Retrogenix’s proprietary cell microarr...